Generate Biomedicines, Inc. balance sheet GENB

As of Jun 30, 2026, Generate Biomedicines, Inc. had total assets of $561.7 million and total liabilities of $105.6 million. Stockholders' equity was $456.0 million. It held $457.4 million in cash and investments against $62.6 million of total debt, net cash of $394.8 million. The current ratio, current assets divided by current liabilities, was 8.30.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
135
161
Short-term investments
322
356
Cash and investments
457
517
Total current assets
470
535
Property and equipment, net
27
28
Total assets
562
626
Liabilities and equity
Accounts payable
6
8
Total current liabilities
57
58
Total liabilities
106
111
Stockholders' equity
456
515
Debt
Lease liabilities
63
66
Total debt
63
66
Net cash
395
451
Ratios
Current ratio
8.30x
9.17x
Debt to equity
0.14x
0.13x
Book value per share
3.56
4.02
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
GENB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Somerville, MA
SEC filer status
, Emerging growth company
SEC CIK
2100782

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.